Zulvac 1 Bovis

RSS

inactivated bluetongue virus, serotype 1

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Zulvac 1 Bovis has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 30/03/2020

Authorisation details

Product details
Name
Zulvac 1 Bovis
Agency product number
EMEA/V/C/002334
Active substance
inactivated bluetongue virus, serotype 1
International non-proprietary name (INN) or common name
inactivated bluetongue virus, serotype 1
Species
Cattle
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI02AA08
Accelerated assessmentAccelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment.

Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Revision
7
Date of issue of marketing authorisation valid throughout the European Union
05/08/2011
Contact address

Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Product information

21/06/2019 Zulvac 1 Bovis - EMEA/V/C/002334 - IB/00017

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunologicals

Therapeutic indication

Active immunisation of cattle from 2½ months of age for the prevention of viraemia caused by bluetongue virus, serotype 1.

Onset of immunity: 15 days after completion of the primary vaccination course.

Duration of immunity: 12 months.

Assessment history

How useful was this page?

Add your rating